Developing novel complement activation assays for application in basic and clinical research
Studying the cross-talk between complement and TLRs, in particular to the co-receptor CD14
Investigating the effect on inflammation by inhibiting complement activation and CD14 using human whole blood in vitro models and in vivo animal models of human diseases
Studying the “Thromboinflammation” and new complex whole blood models to reveal cross-talk between biological systems ex vivo
Studying complement activation in patients with diseases being tentative candidates for future complement intervention
Develop tools for evaluation of the effect of complement therapy in the clinic
Recent publications
Sharifi S, Islam MM, Sharifi H, Islam R, Nilsson PH, Dohlman CH, Mollnes TE, Paschalis EI, Chodosh J(2020) Sputter Deposition of Titanium on Poly(Methyl Methacrylate) Enhances Corneal Biocompatibility Transl Vis Sci Technol, 9(13), 41 DOI 10.1167/tvst.9.13.41, PubMed 33442495
Jøntvedt Jørgensen M, Holter JC, Christensen EE, Schjalm C, Tonby K, Pischke SE, Jenum S, Skeie LG, Nur S, Lind A, Opsand H, Enersen TB, Grøndahl R, Hermann A, Dudman S, Muller F, Ueland T, Mollnes TE, Aukrust P, Heggelund L, Holten AR, Dyrhol-Riise AM(2020) Increased interleukin-6 and macrophage chemoattractant protein-1 are associated with respiratory failure in COVID-19 Sci Rep, 10(1), 21697 DOI 10.1038/s41598-020-78710-7, PubMed 33303843
Keshari RS, Silasi R, Popescu NI, Regmi G, Chaaban H, Lambris JD, Lupu C, Mollnes TE, Lupu F(2020) CD14 inhibition improves survival and attenuates thrombo-inflammation and cardiopulmonary dysfunction in a baboon model of Escherichia coli sepsis J Thromb Haemost DOI 10.1111/jth.15162, PubMed 33174372